Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2

被引：9

作者：

Kandeil, Ahmed ^{[1
]}

Gomaa, Mokhtar R. ^{[1
]}

El Taweel, Ahmed ^{[1
]}

Mostafa, Ahmed ^{[1
]}

Shehata, Mahmoud ^{[1
]}

Kayed, Ahmed E. ^{[1
]}

Kutkat, Omnia ^{[1
]}

Moatasim, Yassmin ^{[1
]}

Mahmoud, Sara H. ^{[1
]}

Kamel, Mina Nabil ^{[1
]}

Shama, Noura M. Abo ^{[1
]}

El Sayes, Mohamed ^{[1
]}

El-Shesheny, Rabeh ^{[1
]}

Yassien, Mahmoud A. ^{[2
]}

Webby, Richard J. ^{[3
]}

Kayali, Ghazi ^{[4
,5
]}

Ali, Mohamed A. ^{[1
]}

机构：

[1] Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Giza, Egypt

[2] Egyptian Drug Author, Biol Sect, Cairo, Egypt

[3] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA

[4] Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77004 USA

[5] Human Link, Hazmieh, Baabda, Lebanon

来源：

PLOS ONE | 2020年 / 15卷 / 10期

基金：

美国国家卫生研究院;

关键词：

NONSPECIFIC PROTECTION; TRAINED IMMUNITY; BCG VACCINATION; INFECTION;

D O I：

10.1371/journal.pone.0241471

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Anecdotal evidence showed a negative correlation between Bacille Calmette-Guerin (BCG) vaccination and incidence of COVID-19. Incidence of the disease in children is much lower than in adults. It is hypothesized that BCG and other childhood vaccinations may provide some protection against SARS-CoV-2 infection through trained or adaptive immune responses. Here, we tested whether BCG, Pneumococcal, Rotavirus, Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae, Hepatitis B, Meningococcal, Measles, Mumps, and Rubella vaccines provide cross-reactive neutralizing antibodies against SARS-CoV-2 in BALB/c mice. Results indicated that none of these vaccines provided antibodies capable of neutralizing SARS-CoV-2 up to seven weeks post vaccination. We conclude that if such vaccines have any role in COVID-19 immunity, this role is not antibody-mediated.

引用

页数：7

共 50 条

[1] Multiple exposures to SARS-CoV-2 Spike enhance cross-reactive antibody-dependent cellular cytotoxicity against SARS-CoV-1
Beaudoin-Bussieres, Guillaume
Tauzin, Alexandra
Dionne, Katrina
El Ferri, Omar
Benlarbi, Mehdi
Bourassa, Catherine
Medjahed, Halima
Bazin, Renee
Cote, Marceline
Finzi, Andres
VIROLOGY, 2025, 607
[2] Cross-reactive memory T cells and herd immunity to SARS-CoV-2
Lipsitch, Marc
Grad, Yonatan H.
Sette, Alessandro
Crotty, Shane
NATURE REVIEWS IMMUNOLOGY, 2020, 20 (11) : 709 - 713
[3] Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naive individuals
Jaago, Mariliis
Rahni, Annika
Pupina, Nadezda
Pihlak, Arno
Sadam, Helle
Tuvikene, Jurgen
Avarlaid, Annela
Planken, Anu
Planken, Margus
Haring, Liina
Vasar, Eero
Bacevic, Miljana
Lambert, France
Kalso, Eija
Pussinen, Pirkko
Tienari, Pentti J.
Vaheri, Antti
Lindholm, Dan
Timmusk, Tonis
Ghaemmaghami, Amir M.
Palm, Kaia
SCIENTIFIC REPORTS, 2022, 12 (01)
[4] Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide
Vanderheijden, Nathalie
Stevaert, Annelies
Xie, Jiexiong
Ren, Xiaolei
Barbezange, Cyril
Noppen, Sam
Desombere, Isabelle
Verhasselt, Bruno
Geldhof, Peter
Vereecke, Nick
Stroobants, Veerle
Oh, Dayoung
Vanhee, Merijn
Naesens, Lieve M. J.
Nauwynck, Hans J.
FRONTIERS IN IMMUNOLOGY, 2022, 12
[5] Nucleic Acid Vaccines against SARS-CoV-2
Liu, Ying
Ye, Qing
VACCINES, 2022, 10 (11)
[6] T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components
Jing, Lichen
Wu, Xia
Krist, Maxwell P.
Hsiang, Tien-Ying
Campbell, Victoria L.
McClurkan, Christopher L.
Favors, Sydney M.
Hemingway, Lawrence A.
Godornes, Charmie
Tong, Denise Q.
Selke, Stacy
LeClair, Angela C.
Pyo, Chu-Woo
Geraghty, Daniel E.
Laing, Kerry J.
Wald, Anna
Gale, Michael, Jr.
Koelle, David M.
JCI INSIGHT, 2022, 7 (06)
[7] Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2
Sharma, Divakar
EXPERT REVIEW OF VACCINES, 2021, 20 (09) : 1051 - 1057
[8] Monoclonal antibody therapies against SARS-CoV-2
Focosi, Daniele
McConnell, Scott
Casadevall, Arturo
Cappello, Emiliano
Valdiserra, Giulia
Tuccori, Marco
LANCET INFECTIOUS DISEASES, 2022, 22 (11) : E311 - E326
[9] Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
Yamayoshi, Seiya
Yasuhara, Atsuhiro
Ito, Mutsumi
Akasaka, Osamu
Nakamura, Morio
Nakachi, Ichiro
Koga, Michiko
Mitamura, Keiko
Yagi, Kazuma
Maeda, Kenji
Kato, Hideaki
Nojima, Masanori
Pattinson, David
Ogura, Takayuki
Baba, Rie
Fujita, Kensuke
Nagai, Hiroyuki
Yamamoto, Shinya
Saito, Makoto
Adachi, Eisuke
Ochi, Junichi
Hattori, Shin-ichiro
Suzuki, Tetsuya
Miyazato, Yusuke
Chiba, Shiho
Okuda, Moe
Murakami, Jurika
Hamabata, Taiki
Iwatsuki-Horimoto, Kiyoko
Nakajima, Hideaki
Mitsuya, Hiroaki
Omagari, Norio
Sugaya, Norio
Yotsuyanagi, Hiroshi
Kawaoka, Yoshihiro
ECLINICALMEDICINE, 2021, 32
[10] SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques
Garrido, Carolina
Curtis, Alan D., II
Dennis, Maria
Pathak, Sachi H.
Gao, Hongmei
Montefiori, David
Tomai, Mark
Fox, Christopher B.
Kozlowski, Pamela A.
Scobey, Trevor
Munt, Jennifer E.
Mallory, Michael L.
Saha, Pooja T.
Hudgens, Michael G.
Lindesmith, Lisa C.
Baric, Ralph S.
Abiona, Olubukola M.
Graham, Barney
Corbett, Kizzmekia S.
Edwards, Darin
Carfi, Andrea
Fouda, Genevieve
Van Rompay, Koen K. A.
De Paris, Kristina
Permar, Sallie R.
SCIENCE IMMUNOLOGY, 2021, 6 (60)

← 1 2 3 4 5 →